Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1015 | 1022 | 1078 | 1058 | 1311 | 1922 |
Fund Return | 1.49% | 2.21% | 7.85% | 1.91% | 5.57% | 6.75% |
Place in category | 566 | 581 | 410 | 223 | 309 | 14 |
% in Category | 76 | 77 | 61 | 39 | 48 | 6 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
VALIC Company I Stock Index | 6.41B | 5.93 | 7.72 | 12.04 | ||
VALIC Company I Mid Cap Index | 3.02B | 3.21 | 2.84 | 9.12 | ||
VALIC Company I Science & Technolog | 2.65B | 8.39 | 2.57 | 16.71 | ||
VALIC Company I International Eqs I | 1.88B | 2.24 | 2.20 | 3.92 | ||
VALIC Company I Growth | 1.69B | 8.16 | 4.71 | 13.20 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Intl Stock Index Inv | 195.27B | 1.91 | 0.13 | 4.01 | ||
Vanguard Total Intl Stock Index Adm | 75.19B | 1.95 | 0.19 | 4.07 | ||
Fidelity International Index Inst | 48.57B | 2.55 | 2.86 | 4.45 | ||
Fidelity Series Global ex US Index | 44.6B | 2.31 | 0.29 | 3.89 | ||
Vanguard Total Intl Stock Index I | 40.77B | 1.97 | 0.22 | 4.10 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Msci Eafe Mar24 Ifus 20240315 | - | 4.81 | - | - | |
ASML Holding | NL0010273215 | 2.43 | 864.50 | +1.96% | |
Novo Nordisk B | DK0062498333 | 2.32 | 883.2 | +0.07% | |
SAP | DE0007164600 | 1.37 | 176.060 | -0.97% | |
Novartis | CH0012005267 | 1.17 | 92.32 | +1.97% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review